Revenue grew year-over-year, but a significant rise in R&D and SG&A costs contributed to a higher net loss. Cash reserves strengthened following a major equity raise, extending the company’s runway into 2029.

uniQure reported a net loss of $43.6 million for Q1 2025, an improvement from $65.6 million in Q1 2024. Revenues decreased to $1.6 million from $8.5 million in the prior year, primarily due to the divestment of the Lexington facility. The company's cash position increased to $409.0 million, expected to fund operations into the second half of 2027.

uniQure reported a net loss of $239.6 million for the year ended December 31, 2024. The company is focusing on advancing its gene therapy pipeline, particularly AMT-130 for Huntington's disease, and has streamlined operations to extend its cash runway into the second half of 2027.

uniQure announced its Q3 2024 financial results, highlighting clinical advancements in its gene therapy programs, including AMT-130 for Huntington's disease, and the initiation of new Phase I/II studies. The company also completed the sale of its Lexington manufacturing facility and implemented an organizational restructuring to reduce operating expenses, extending its cash runway through the end of 2027. Revenue increased compared to the same period in 2023, while net loss decreased.

uniQure announced its second quarter 2024 financial results, highlighting an increase in revenue to $11.1 million compared to $2.4 million in the same period last year. This growth was driven by collaboration, license, and contract manufacturing revenues. The company reported a net loss of $56.3 million, or $1.16 per share, compared to a net loss of $68.5 million, or $1.44 per share, for the same period in 2023. uniQure is focusing on advancing its clinical pipeline and reducing capital requirements to extend its cash runway through the end of 2027.

uniQure made progress on key business priorities in Q1 2024, including advancing AMT-130 for Huntington's disease, initiating new clinical trials, and conserving capital. The company is on track to initiate FDA interactions regarding AMT-130 and provide a clinical update from Phase I/II trials in mid-2024. Enrollment for the Fabry disease study is on track to begin in Q2 2024, with SOD1-ALS and MTLE studies expected to begin in Q3.

uniQure announced its Q4 and full year 2023 financial results. The company's cash position is expected to fund operations into the second quarter of 2027. Strategic reorganization is expected to deliver $180 million of cost savings over the next three years.

uniQure reported Q3 2023 revenues of $1.4 million, consistent with the previous year. The company experienced a net loss of $89.6 million, compared to a $47.9 million loss in the same period of 2022. They announced FDA clearance for AMT-260 and are on track to provide a clinical update on AMT-130. A strategic reorganization is expected to save $180 million over three years, with a strong cash position of approximately $660 million.

uniQure announced its financial results for the second quarter of 2023, highlighting encouraging data from its AMT-130 Huntington's disease trial and preparations for new clinical trials. The company's cash position is strong with $628.6 million, excluding a $100 million milestone received in July.

uniQure reported a net loss of $77.2 million for Q1 2023, with revenue increasing to $5.3 million compared to $1.8 million in the same period last year. The company's cash and cash equivalents totaled $315.3 million as of March 31, 2023.

uniQure had a strong ending to 2022 with the approval of the world’s first gene therapy for hemophilia B. The company is working to advance AMT-130 and preparing for the initiation of two new Phase I/II studies in refractory temporal lobe epilepsy and SOD1-ALS.

uniQure's Q3 2022 collaboration revenue was $1.4 million, R&D expenses were $48.1 million, and SG&A expenses were $13.3 million. The company's net loss for the quarter was $47.9 million, or $1.02 per share. As of September 30, 2022, the company held $440.3 million in cash and cash equivalents.

uniQure announced encouraging data from the lower-dose cohort in its Phase I/II study of AMT-130 and the advancement of the U.S. and European regulatory reviews for the marketing applications for etranacogene dezaparvovec in hemophilia B. The company held cash and cash equivalents of $500.5 million as of June 30, 2022.

uniQure reported a strong start to 2022, marked by advancements in key programs, progress in research activities, and the strengthening of its executive leadership team. Partner CSL Behring submitted a Marketing Authorization Application in Europe for etranacogene dezaparvovec. The company received $55 million in milestone payments, and made significant advancements enrolling patients in Phase I/II studies for AMT-130 in Huntington’s disease, completing 32 patient procedures to date.

uniQure reported a strong financial year, ending with $556.3 million in cash and cash equivalents. The company's revenue significantly increased due to the CSL Behring transaction and milestone payments. Net income was $329.6 million, a substantial improvement compared to the previous year's loss.

uniQure reported its financial results for the third quarter of 2021. The company held cash and cash equivalents of $578.5 million as of September 30, 2021. Revenue for the quarter was $2.0 million, and the net loss was $36.5 million, or $0.79 basic and diluted net loss per share.

uniQure had a productive second quarter, marked by the closing of a global commercial licensing agreement with CSL Behring in hemophilia B and the presentation of positive 52-week data from the HOPE-B pivotal study. The company also disclosed four new research programs and announced the acquisition of Corlieve Therapeutics.

uniQure reported its financial results for the first quarter of 2021. The company held cash and cash equivalents of $260.8 million as of March 31, 2021. Revenue for the quarter was $0.5 million, and the net loss was $41.6 million, or $0.91 loss per share.

uniQure reported its financial results for 2020, including a revenue of $37.5 million and a net loss of $125.0 million. The company completed patient dosing in the HOPE-B pivotal trial and announced a transaction with CSL Behring for the commercialization of etranacogene dezaparvovec.

uniQure reported revenue of $1.8 million and a net loss of $53.8 million for the third quarter of 2020. The company held cash and cash equivalents of $279.5 million as of September 30, 2020.

uniQure reported its financial results for the second quarter of 2020. They entered into an exclusive global license agreement with CSL Behring for their gene therapy candidate for hemophilia B and completed the first patient dosing in a Phase I/II clinical trial of AMT-130 in Huntington’s Disease.

uniQure ended the first quarter of 2020 in a position of strength with cash and cash equivalents of $342.0 million. The company reported revenue of $0.1 million and a net loss of $28.0 million, or $0.63 loss per share.

uniQure reported a net loss of $124.2 million for the year ended December 31, 2019. The company held cash and cash equivalents of $377.8 million as of December 31, 2019, which is expected to fund operations into 2022.